Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab in previously treated advanced anal cancer
NCT03597295Phase 2Completed
- Sponsor
- Incyte
- Start
- Oct 2018
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of retifanlimab in anal canal squamous cell carcinoma (SCCA), sponsored by Incyte. Started Oct 2018; status: completed.
02
Drugs
retifanlimab
03
Conditions
anal canal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT03597295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03597295.